Navigation Links
Synosia Starts Phase II Efficacy Trial For Rufinamide
Date:3/31/2008

The drug was originally discovered and developed by Novartis, which in 2004 granted certain licensing rights to Eisai, excluding anxiety and mood disorders. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company has six clinical-stage compounds in its pipeline, acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's headquarters is in Basel, Switzerland. For more information visit http://www.synosia.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

References

'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
5. Evotec Starts Phase II in Smoking Cessation with EVT 302
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... 2014  FlexTech Alliance today issued a dual-focused ... demonstrators (demos) and a functional electronic print leaflet.  ... due on October 22, 2014 and full proposals ... selected are provided by the US Army Research ... by the proposing organization. Photo - ...
(Date:9/15/2014)... has sepsis, a life-threatening condition in which bacteria or ... fast for antibiotics to help. A new device inspired ... at Harvard,s Wyss Institute for Biologically Inspired Engineering may ... "Even with the best current treatments, sepsis patients are ... of the time," said Mike Super, Ph.D., Senior Staff ...
(Date:9/15/2014)... interdisciplinary team of researchers led by Northeastern University ... precise inter-nanotube junctions and a variety of nanocarbon ... facile and easily scalable, which will allow the ... networks for use in applications ranging from electronic ... from cars to sports equipment. , Their findings ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Inc. (Nasdaq: ECTE ), a company developing ... continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep ... from its clinical study of its Symphony tCGM System ... Data from the study confirm that Symphony successfully monitors ...
... create electrical components like resistors, transistors and diodes, that ... Nongjian (NJ) Tao, a researcher at the Biodesign Institute ... molecules may also allow clever designers to produce novel ... conventional electronics. In research appearing in today,s ...
... YORK, Dec. 5, 2011 Levi & Korsinsky is ... securities of Pacific Biosciences of California, Inc. ("PacBio" or ... violations of federal securities laws. For more ... The investigation stems from allegations that the Company failed ...
Cached Biology Technology:Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4S-t-r-e-t-c-h-i-n-g electrical conductance to the limit 2S-t-r-e-t-c-h-i-n-g electrical conductance to the limit 3The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc. 2
(Date:9/16/2014)... Scotland votes for independence later this week, its Government ... people that fracking is necessary, research has revealed. , ... tracking public perception of shale gas extraction in the ... living north of the border are the least supportive ... research in the University,s School of Geography, said: "The ...
(Date:9/16/2014)... From the salmon-rich waters of Southeast Alaska to ... Downeast Maine,s lobster, lumber and tourist towns, coastal residents ... about coastal environments divide along political lines. That,s a ... New Hampshire sociologists published this month in the journal ... a lot of environment-related differences from place to place ...
(Date:9/16/2014)... years ago, the Exxon Valdez spilled 11 million gallons ... themselves cleaning up another giant oil spill in the ... study in the Journal of Consumer Research , ... immediate anxieties instead of catalyzing changes in the way ... national news media coverage of these two events helped ...
Breaking Biology News(10 mins):Scottish people most sceptical on fracking, survey shows 2Scottish people most sceptical on fracking, survey shows 3Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2
... summer for sports, fans. World records tumbled at the ... 200m world records, knocking tenths of a second off ... the last few decades, which made marathon runner Mark ... increase in population could account for these dramatic improvements. ...
... genetic polymorphisms induce major differentiations in the metabolic ... paper published November 28 in the open-access journal ... of researchers, led by Karsten Suhre, has conducted ... variants in genes involved in the breakdown of ...
... A new and insidious environmental threat has been ... Queen,s and York universities. Along with scientists ... documented biological damage caused by declining levels of ... the phenomenon "aquatic osteoporosis," Queen,s PhD candidate Adam ...
Cached Biology News:100-meter sprint world record could go as low as 9.48 seconds 2Study identifies genetic variants giving rise to differences in metabolism 2Queen's University biologists find new environmental threat in North American lakes 2
... Decorin ( Abpromise for all ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to ... of Human Decorin (fragment 36-49 of ... Entrez GeneID: ...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
... System is a fluorescent microscopy-based imaging system ... cells and automatically calculates cell viability, in ... routine function, the variability associated with the ... eliminated. Using the EasyCount ViaSure Kit, up ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
Biology Products: